Emmanuel Gyan1,2,3, François Dreyfus3,4 and Pierre Fenaux3,5
1 Service d’hématologie et thérapie cellulaire, Centre hospitalier universitaire, Tours, France
2 Team 2 "Leukemic Niche and Redox metabolism", UMR CNRS 7292 GICC, Université François Rabelais, Tours, France
3 Groupe Francophone des Myélodysplasies, Hôpital Saint Louis, AP-HP, Paris, France
4 Service d’hématologie, Hôtel-Dieu, AP-HP, Paris, France
5 Service d’hématologie séniors, Hôpital Saint Louis, AP-HP and Paris 7 University, Paris, France
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The 2008 WHO classification identified refractory cytopenia with unilineage dysplasia (RCUD) as a composite entity encompassing refractory anemia, refractory thrombocytopenia (RT), and refractory neutropenia (RN), characterized by 10% or more dysplastic cells in the bone marrow respective lineage. The diagnosis of RT and RN is complicated by several factors. Diagnosing RT first requires exclusion of familial thrombocytopenia, chronic auto-immune thrombocytopenia, concomitant medications, viral infections, or hypersplenism. Diagnosis of RN should also be made after ruling out differential diagnoses such as ethnic or familial neutropenia, as well as acquired, drug-induced, infection-related or malignancy-related neutropenia. An accurate quantification of dysplasia should be performed in order to distinguish RT or RN from the provisional entity named idiopathic cytopenia of unknown significance (ICUS). Cytogenetic analysis, and possibly in the future somatic mutation analysis (of genes most frequently mutated in MDS), and flow cytometry analysis aberrant antigen expression on myeloid cells may help in this differential diagnosis. Importantly, we and others found that, while isolated neutropenia and thrombocytopenia are not rare in MDS, those patients can generally be classified (according to WHO 2008 classification) as refractory cytopenia with multilineage dysplasia or refractory anemia with excess blasts, while RT and RN (according to WHO 2008) are quite rare. These results suggest in particular that identification of RT and RN as distinct entities could be reconsidered in future WHO classification updates.
Background: WHO Classification of MDS
Myelodysplastic syndromes (MDS) are marrow stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, a variable proportion of blasts, and a propensity to evolve to acute myeloblastic leukemia (AML). The first classification of MDS was published by the French-American-British group in 1982, individualizing five entities named refractory anemia (RA), refractory anemia with ringed sideroblasts, RA with excess blasts (RAEB), RA with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML). This FAB MDS classification, mainly based on the morphologic features of the blood and the bone marrow was refined in 2002 and finally in 2008 by the World Health Organization, that shifted the RAEB-T category to AML by lowering the threshold of bone marrow blasts for AML diagnosis from 30% to 20%, also excluded CMML from MDS, individualized MDS with isolated deletion of the long arm of chromosome 5 (del 5q), and took into account the number of morphologically dysplastic myeloid lineages. This led to separate, in patients without excess of marrow blasts, those with multilineage dysplasia (refractory cytopenia with multilineage dysplasia or RCMD, with or without ringed sideroblasts) from patients with unilineage dysplasia (refractory cytopenia with unilineage dysplasia or RCUD) (Table 1).
RCUD as a Distinct Diagnostic Group in the 2008 WHO Classification
RCUD was thus identified as a new MDS group, containing three
arbitrarily defined subgroups: refractory anemia (RA), refractory
neutropenia (RN) and refractory thrombocytopenia (RT). It is important
to consider that these diagnoses are mainly based on the bone marrow
finding of a unique dysplastic lineage, contrarily to what their name
would intuitively suggest. The characteristics of WHO-defined RCUD are
Common characteristics of RCUD. Marrow findings should be unilineage dysplasia defined as the presence of ≥ 10% dysplastic cells in one myeloid lineage. Less than 5% blasts are observed. The blood should contain < 1% blasts. Cases of unilineage dysplasia with 1% circulating blasts should be classified as MDS-U. If 2-4% circulating blasts are observed, the diagnostic classification is RAEB-1. Even though RARS has unilineage dysplasia, it is recognized as a distinct entity and not included in RCUD. Therefore, RA diagnosis is considered when only erythroid dysplasia is present and if < 15% ringed sideroblasts.
For the diagnosis of MDS, cytopenias are defined as hemoglobin < 10 g/dL, absolute neutrophil count (ANC) < 1.8x109/L, and platelet count < 100x109/L. Importantly, two cytopenias are accepted for the diagnosis of RCUD, provided there is only one dysplastic lineage in the bone marrow. In case of pancytopenia associated with only one dysplasia in the bone marrow, the classification should be MDS-U (Table 1). Also, the cytopenia does not always correspond to the bone marrow dysplastic lineage. In a series of 44 patients with a single cytopenia with unilineage dysplasia described by Verburgh et al, 18 (41%) presented with a cytopenia in a lineage not affected by dysplasia. This discrepancy creates an ambiguity in the understanding of the RCUD subgroups, theoretically characterized by one ‘refractory cytopenia’ (RA, RN, or RT), since a unique cytopenia in a patient with MDS may be associated in some cases with ≥ 10% bone marrow dysplasia in another or several lineages. There is thus an ‘unilineage paradox’, where the WHO-defined RCUD can be associated with one or two cytopenias not corresponding with the affected lineage in the bone marrow, whereas MDS with only one cytopenia – which could be identified as ‘isolated thrombocytopenia’ (IT) or ‘isolated neutropenia’ (IN) – are common. This issue will be discussed below.
In refractory anemia (RA), signs of dyserythropoiesis may be observed on blood smears, such as macrocytosis, anisochromasia or dimorphism, with or without anisocytosis and poikilocytosis, which are markers of clonal heterogeneity in a chimeric bone marrow. Neutrophils and platelets are usually normal in number and morphology. However, the presence of moderate neutropenia or thrombocytopenia remains consistent with the diagnosis of RA. Bone marrow cellularity is generally increased, but can be normal or decreased. Dyserythropoiesis is defined as 10% or more dysplastic erythroid precursors. Dysery-thropoiesis is not specific for RCUD compared to other types of MDS. If a dysplasia is present in a second lineage, it should always be < 10%.
In refractory neutropenia (RN), dysgranulopoiesis can be identified in the blood by the presence of nuclear hypolobation and hypogranulation of neutrophils. In the bone marrow, dysplasia in the granulocytic lineage is ≥10%, with no significant dysplasia (<10%) in the erythroid or megakaryocytic lineage.
Refractory Thrombocytopenia (RT) is mainly characterized in the blood by isolated thrombo-cytopenia. A second cytopenia may be associated. In the bone marrow, RT is characterized by ≥10% dysplasia evaluated on at least 30 megakaryocytes. Dysmegakaryopoiesis may include hypolobated megakaryocytes, multinucleated megakaryocytes and micromegakaryocytes. The other cell lineages are not affected, or may display non-significant dysplasia (<10%).
|Table 1.WHO 2008 classification of MDS|
Differential Diagnosis of RT
Following the exclusion of pseudothrombocytopenia, isolated
thrombo-cytopenia of RT should mainly be distinguished from chronic
immunologic thrombocytopenic purpura (ITP) and familial
thrombocytopenia (Table 2). RT
may be overlooked if bone marrow evaluation is not performed. For this
reason, the bone marrow examination should be performed in any patient
with an isolated confirmed thrombocytopenia above the age of 60
years. A complete workup for thrombocytopenia should be performed
with viral serology, careful medical history with an inquiry about all
possible concomitant medications is needed. Cytogenetic studies are of
clear interest in this distinction, since 20q deletion has frequently
been reported in RT,[6–8] or more rarely other cytogenetic
abnormalities such as del(5q). Furthermore, even in MDS, an
autoimmune destruction of platelets can contribute to thrombocytopenia.
Platelet lifespan studies (and of their sequestration) by radioisotopic
methods can be of interest to analyze the various mechanisms of
thrombocytopenia, and help in therapeutic decision-making.
Anti-platelet autoantibodies have a low sensitivity for the diagnosis
of ITP, and, although they are frequently positive in MDS but
they do not help very much to identify a mixed pathophysiology of
thrombocytopenia. Platelet morphology on blood smears can be
helpful for diagnostic orientation. Giant platelets or
microthrombocytes can be secondary to hereditary thrombocytopenias of
childhood, or associated infections. Associated morphological
abnormalities such as Pelger-Huët bilobed nuclei, or evidence of
dysgranulopoiesis may be suggestive of MDS, whereas abnormal
hematopoietic cells may orient the diagnosis towards a hematologic
|Table 2. Differential diagnosis of RT|
Differential Diagnosis of RN
|Table 3. Differential diagnosis of RN|
Getting Appropriate Material for Morphological Diagnosis
Distinguishing between RCUD and Borderline EntitiesThe WHO 2008 classification proposed an entity named idiopathic cytopenia of unknown significance (ICUS), defined as a condition with less than 10% dysplastic cells, fewer than 5% blasts in the bone marrow and no cytogenetic abnormalities.[3,20] These patients most often present with mild cytopenias, and if the morphologist is unaware of the complete medical history, the diagnosis might be reported as “abnormalities not sufficient for the diagnosis of MDS”, when the cytogenetic study is normal. Differential diagnosis of ICUS, like for RCUD, includes autoimmune disorders, drug intake, chronic infections, paroxysmal nocturnal hemoglobinuria, and appropriate explorations need to be carried out.[21,22] ICUS patients should be followed to document or exclude hematological evolution to an authentic MDS, most importantly by repetition of the BM examination with cytogenetic studies if the cytopenia worsens or if a second cytopenia develops. One should also bear in mind that dysplastic changes can be seen in up to 9,5% of the erythroid or granulocytic bone marrow cells in elderly persons and in smokers.
RT and RN are RareApart from RA, the other RCUD (RT and RN) appear to be rare. In a cytomorphologic study of 3156 MDS patients from the Düsseldorf MDS registry, the diagnosis of RCUD was made in 218 (7%). When the Düsseldorf group revaluated, by WHO 2008 diagnostic criteria, 193 RA according to WHO 2001, the following diagnoses were found: 37 RCUD (19%), 6 MDS-U (3%), 111 RCMD (58%), and 39 5q- syndromes (20%), but a higher proportion of RCUD (45%) was found in the Japanese registry. To assess the RCUD and MDS-U categories in 196 patients with less than 5% marrow blasts, Maassen et al. found 28% RA, 6% RT, 13% RN, 20% patients with no cytopenia, and 34% patients with bicytopenia. Another retrospective study on 293 MDS in a single institution identified 5 RN (1.7%) and 6 RT (2.0%) only. Furthermore, in a study combining 228 MDS patients from the Italian, Düsseldorf and GFM registries presenting with isolated neutropenia (IT) (< 1.5 x 109/L) or isolated thrombocytopenia (IT) (< 100 x 109/L) and no anemia, we found only 3 (1%) RT and no RN (Gyan et al., submitted). The most frequent diagnosis found in patients with IT or IN was RCMD (32 %) and RAEB 1 (18 %), which occurred at similar frequency in both types. Furthermore, during evolution, RT or RN patients often develop additional cytopenias, which is consistent with the hypothesis that RT and RN are early presentations of refractory cytopenias with multilineage dysplasia. This observation further suggests that real WHO-defined RT and RN are very rare – if they even exist – whereas MDS patients with only one cytopenia most often show dysplasia in multiple lineages.
Prognosis of RT and RNRCUD is associated with a more favorable outcome than RCMD.[4,36] In a comparative study between the Düsseldorf and the Japanese MDS registries, median overall survival of RCUD and RCMD was 202 months vs. 109 months in the Japanese cohort, respectively, and 142 months vs. 36 months in the German cohort, respectively, with statistical significance. It is important to try to distinguish RCUD patients with a high and low risk of evolution to RAEB or AML. In a series of 126 patients with RCUD, RT diagnosis was associated with shorter OS (median 15.9 months) then RA (median 48.2 months) and RN (median 35.9 months, p<0.001). In another study, the number of RT and RN was too low to identify a statistically different outcome, but median survival was 32.5 months and 72 months for RT and RN, respectively. In a bone marrow flow cytometry analysis of patients with RCUD, Oka et al. described a lower content of CD19+ or CD10+ lymphoid cells in the marrow blast region (CD45int/side scatterlow) of patients in whom circulating blasts appeared during follow-up, compared to patients who did not experience disease evolution to higher risk MDS or AML.
Diagnostic Tools for the Diagnosis of RT and RNFlow cytometry (FC) is able to identify aberrant expression patterns of lineage antigens in the erythroid, granulo-monocytic and lymphoid lineages, and a collaborative effort has proposed guidelines for the FC recognition of dysplasia. Since RCUD displays a variable level of dysplastic cells in one lineage only, FC may be a valuable tool for the identification of MDS FC signatures. Moreover, a FC score may help to distinguish MDS from other nonmalignant reactive or secondary cytopenias,[42,43] and support the diagnosis of IDUS, which may represent a pre-phase of MDS. The Ogata score, based on a 4-color analysis of 13 antigens, has shown a sensitivity of 70% and a specificity of 92% in the whole MDS group. For RCUD, the sensitivity was 62%, and a specificity reaching 97% in distinguishing MDS from immune cytopenias. Additionally, a FC score is likely to bring prognostic information in MDS even when the blast count is below 5%, with a high correlation with transfusion dependency, cytogenetics, and the IPSS score. In addition, a higher number of aberrantly expressed antigens detected by FC has been associated with worse survival. Altogether, the available data support the use of FC as a diagnostic tool to increase the accuracy of RCUD diagnosis, as well as for the diagnosis of differential conditions, such as PNH.
Funding. This work was not supported by any academic, associative, or industrial funding.
Author contributions. E.G., F.D., and P.F. analyzed literature data and wrote the paper.
Conflict-of-interest. E.G. received research grants from Celgene, Janssen, Fresenius Kabi, and Novartis. P.F. and F. D. declare no conflict-of-interest.